New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
07:07 EDTBLUEbluebird bio recommended ahead of trial updates at JPMorgan
JPMorgan recommends owning shares of bluebird bio ahead of upcoming clinical trial updates. The firm notes initial data from the Phase 1/2 HGB-205 study evaluating LentiGlobin in beta-thalassemia patients will be presented on June 14 at the European Hematology Association. JPMorgan has an Overweight rating on the stock with a $44 price target.
News For BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 3, 2016
10:00 EDTBLUEOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Capella Education (CPLA) initiated with an Outperform at Credit Suisse... DeVry (DV) initiated with an Outperform at Credit Suisse... Gilead (GILD) initiated with a Buy at Standpoint Research... Grand Canyon (LOPE) initiated with a Neutral at Credit Suisse... Hannon Armstrong (HASI) initiated with an Equal Weight at Morgan Stanley... Houghton Mifflin (HMHC) initiated with an Outperform at Credit Suisse... Mediaset (MDIUY) initiated with a Buy at Jefferies... Palo Alto (PANW) initiated with a Buy at Maxim... Splunk (SPLK) initiated with a Buy at Maxim... Strayer (STRA) initiated with a Neutral at Credit Suisse... Tableau (DATA) initiated with a Sell at Maxim... Tesla (TSLA) initiated with a Sell at Berenberg... WisdomTree (WETF) initiated with an Outperform at Northland... bluebird bio (BLUE) initiated with an Outperform at Leerink.
08:02 EDTBLUEbluebird bio initiated with an Outperform at Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use